[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-preserved-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-preserved-ejection-fraction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,78,106,130,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100606637","phase-4-epicardial-adipose-tissue-composition-and-heart-failure-with-preserved-ejection-fraction-100606637",false,"NCT07178145","Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction","MRI of Epicardial Adipose Tissue Composition: Development of Methods and Application to Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years - 90 years;\n* LVEF ≥ 50%;\n* ≥ 2 risk factors for HFpEF or symptoms that could be related to HFpEF (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, pulmonary edema, etc);\n* Not currently being treated with GLP-1RA therapy.\n\nExclusion Criteria:\n\n* • Previously or currently reduced EF (\\\u003C50%), including heart transplant; (2) Obstructive un-revascularized coronary disease by coronary CT or invasive coronary angiography;\n\n  * MI\u002FPCI\u002FCABG within the past 6 months;\n  * Untreated severe stenotic or regurgitant valvular disease;\n  * Infiltrative cardiomyopathy (Fabry\u002FHCM\u002Fsarcoid\u002Famyloid, etc);\n  * Myocarditis;\n  * Claustrophobia\u002Finability to tolerate MRI;\n  * Implants that are a contraindication for MRI or may negatively impact image quality (e.g. pacemakers and ICDs);\n  * Active systemic inflammatory disorder;\n  * Atrial fibrillation with rapid ventricular response at time of study; and\n  * Hemodynamic instability\n  * Pregnancy\n  * Prisoners\n  * Inability to provide informed consent\n\nExclusion Criteria for Optional Cardiac Stress Imaging Procedure\n\n* allergy to gadolinium-based contrast agents\n* Acute kidney injury\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* Hepatorenal syndrome\n* History of liver transplant\n* High-grade atrioventricular (AV) block\n* Active asthma exacerbation\n* Known allergy to vasodilator agents\n* Recent seizure","ALL","18 Years","90 Years",{"count":20,"type":21},192,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the relationship between EAT and heart failure with preserved ejection fraction (HFpEF) and (b) for understanding mechanisms of and guiding medical therapy in HFpEF. The investigators recently developed the first method for quantifying EAT FAC in human subjects, utilizing a rate-6 accelerated radial 2D multi-echo gradient-echo breathhold acquisition with a local low rank reconstruction. In this project the first specific aim is to develop a rapid free-breathing 3D EAT FAC MRI method that reduces motion-related artifacts, increases coverage, and facilitates higher spatial resolution and improved FAC reproducibility. The second specific aim is to show that EAT FAC is more strongly associated than EAT volume with cardiometabolic HFpEF. In this context, individuals with known or suspected HFpEF will undergo CMR, echocardiography, and other testing to (a) diagnose cardiometabolic HFpEF; (b) characterize features associated with the severity of HFpEF; and (c) assess EAT volume and FAC. The investigators will determine if EAT FAC is more strongly associated than EAT volume with HFpEF and with features associated with the severity of HFpEF. The third specific aim is to show, in the context of cardiometabolic HFpEF and pre-HFpEF, (a) that GLP-1 receptor agonism with semaglutide (SEMA) shifts the EAT FAC to a less proinflammatory profile and (b) that baseline EAT FAC is a stronger predictor than EAT volume of improved cardiovascular function due to SEMA. Cardiometabolic HFpEF and pre-HFpEF subjects will undergo echocardiography and CMR with EAT FAC at baseline and after 3 months to serve as a self-control. Subjects will then undergo repeat imaging 6 months after the initiation of SEMA. The change in FAC after treatment with SEMA will be compared to the change in FAC prior to SEMA. Data will be analyzed to show that SEMA changes EAT FAC, and that baseline EAT FAC is a stronger predictor than EAT volume of improvements in severity of HFpEF.",[27,28],"Heart Failure Preserved Ejection Fraction","Epicardial Adipose Tissue",[30,31,32,28,33,34,35],"HFpEF","Heart Failure preserved Ejection Fraction","Cardiac MRI","GLP-1","EAT FAC","cardiovascular function","RECRUITING","2026-04-28",{"date":39,"type":40},"2026-05-05","ACTUAL",{"date":42,"type":40},"2025-11-20",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"University of Virginia","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100573066","exercise-testing-after-preeclampsia-100573066","NCT06741436","Exercise Testing After Preeclampsia","Identification of Early HFpEF After Preeclampsia by Exercise Stress Testing","Inclusion Criteria:\n\n1. Women age \\> 18 years\n2. Give birth at VUMC\n3. Have a diagnosis of PreE based on accepted American College of Obstetricians and Gynecologists criteria\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old\n2. Unable to provide informed consent\n3. Does not speak English\n4. Active COVID-19 infection\n5. Residual symptoms related to prior COVID-19 infection\n6. HIV infection\n7. Hepatitis B or C infection\n8. Pulmonary arterial hypertension\n9. Sickle cell disease\n10. Pulmonary embolism\n11. Pre-existing cardiomyopathy\n12. Coronary artery disease\n13. Active substance abuse (other than tobacco or marijuana)\n14. Unable to attend postpartum visits\n\nControls\n\n1\\. Enrolling controls who meet the same inclusion\u002Fexclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.",true,"FEMALE",{"count":59,"type":21},500,"OBSERVATIONAL","Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular system. Recent data from the investigators and others has highlighted pregnancy as a unique, early moment of cardiovascular stress in young women that may \"unmask\" CVD propensity. It is unclear if PreE simply represents a \"failed stress test\" or directly contributes to the pathophysiology of future CVD. While mechanistic studies have largely been the purview of model-based studies, endothelial dysfunction has emerged as central to the pathogenesis of both PreE and peripartum cardiac dysfunction. Indeed, biomarkers of endothelial dysfunction and angiogenic imbalance during pregnancy have been shown to remain elevated at least 6 months post-partum. Moreover, peri-partum endothelial dysfunction can persist for years post-delivery and remains a significant risk factor for CVD (even after adjustment for other traditional risk factors). While these findings suggest that PreE-associated endothelial dysfunction and inflammation may contribute to early myocardial dysfunction that presages HF risk decades before its onset, the modifiable epidemiology of PreE-associated LVDD, including potential mechanisms of risk, remains unclear, limited by lack of precision molecular phenotypes accessible in a large number of American women across race. Ultimately, understanding the epidemiology and pathobiology of PreE-associated myocardial dysfunction affords a unique opportunity to identify women at risk with a longer lead-time for risk factor modification to interrupt CVD.\n\nThe investigators hypothesize that persistent structural-functional myocardial alterations after PreE are linked to pre- and post-gravid cardiometabolic risk factors (SA1), functional and hemodynamic impairment (SA2) and select pathways of vascular and inflammatory stress relevant to HF risk (SA3). Despite extensive study on the role of inflammation\u002Fischemia in PreE, there have been no large studies connecting these phenotypes with early PP functional response and biochemical alterations, a key barrier to designing studies for improving CVD\u002FHF in women.\n\nSA1: To identify pregnancy-specific clinical factors related to postpartum HFpEF phenotypes Clinical Implication: Improve identification of women at highest risk for developing post-PreE LV diastolic dysfunction (a harbinger of HFpEF).\n\nSA2: To define functional and hemodynamic signatures of early HFpEF due to preeclampsia\n\nClinical Implication: Identify women at highest risk for developing early HFpEF.\n\nSA3: To identify shared pathophysiologic mechanistic pathways for PreE-associated HFpEF Clinical Implication: Identify targetable pathways for post-PreE cardiac dysfunction that may prevent\u002F delay HFpEF development.",[63,27,64],"Preeclampsia","Hypertension",[66,67,68],"CPET","Placental vascular dysfunction","echo","2026-04-13",{"date":71,"type":40},"2026-04-14",{"date":73,"type":40},"2025-02-18",{"date":75,"type":21},"2029-06-30",{"name":77,"class":47},"Vanderbilt University Medical Center",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100611197","cardiovascular-and-renal-endpoints-with-flozins---an-observational-prospective-study-in-ckd-hfpef-patients-100611197","NCT07237451","Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients","CARE FOR CKD H","Inclusion Criteria:\n\n* age\\>18 years;\n* ejection fraction \\> 40;\n* patients with CKD stage 3-4 (eGFR between 15-60 mL\u002Fmin\u002F1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;\n* age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.\n\nExclusion Criteria:\n\n* eGFR\\\u003C 15 mL\u002Fmin\u002F1.73m2 or patients undergoing dialysis;\n* presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies;\n* coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions);\n* cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers;\n* active systemic infections (due to interference with biomarkers that can give false rise values).",{"count":86,"type":21},200,"The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.",[89,27,90,91],"CKD - Chronic Kidney Disease","SGLT2 Inhibitors","Diabetes (DM)",[93,30,94,95,96],"CKD","SGTL2 inhibitors","Biomarkers","PWV","2025-11-16",{"date":99,"type":40},"2025-11-19",{"date":101,"type":40},"2025-01-08",{"date":103,"type":21},"2027-12-31",{"name":105,"class":47},"Grigore T. Popa University of Medicine and Pharmacy",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100551990","mechanistic-insights-from-temporary-pacing-in-hfpef-100551990","NCT06467266","Mechanistic Insights From Temporary Pacing in HFpEF","Mechanistic Insights From Multisite Pacing in Patients With Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 years or above.\n* Formal diagnosis of HFpEF as per ESC guidelines\n* NYHA grade II-IV heart failure symptoms\n* LVEF ≥50%\n* Female participants of child-bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter\n* Able (in the Investigators opinion) and willing to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\n* History of persistent or permanent AF\n* Permanent pacing device in situ\n* Female participants who are pregnant, lactating or planning pregnancy during the course of the study.\n* Scheduled elective surgery or other procedures requiring general anaesthesia during the study.\n* Participant who is terminally ill\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Significant peripheral vascular disease precluding an EP study\n* A contraindication to anticoagulation\n* A prosthetic aortic, mitral or tricuspid valve\n* Significant Aortic valve disease\n* Known LV thrombus\n* Insufficient capacity to consent to the study\n* Participation in other studies with active treatment \u002F investigational arm to avoid bias",{"count":114,"type":21},10,[116],"NA","Heart failure with preserved ejection fraction (HFpEF) is characterised by impaired diastolic function. A recent clinical trial has demonstrated multiple beneficial outcomes in HFpEF patients receiving personalised accelerated pacing from indwelling permanent pacemakers, including symptomatic improvement, objective reductions in NT-proBNP level and AF-burden.\n\nThe investigators aim to determine the underlying mechanisms behind these documented effects, to investigate the acute intracardiac haemodynamic response to temporary multisite pacing in HFpEF participants and to gain further mechanistic insight with additional haemodynamic, electrical and echocardiographic data collection during temporary pacing in this cohort. This will all provide valuable information towards new potential targets of therapy.",[27,119],"Pacing","NOT_YET_RECRUITING","2024-06-14",{"date":123,"type":40},"2024-06-20",{"date":125,"type":21},"2024-07-01",{"date":127,"type":21},"2026-10-31",{"name":129,"class":47},"Guy's and St Thomas' NHS Foundation Trust",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":48},"100543024","phase-4-the-efficacy-of-enavogliflozin-in-heart-failure-with-preserved-ejection-fraction-100543024","NCT06350487","The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction","The Efficacy of Enavogliflozin on Exercise Performance and Diastolic Function in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial","ENRICH-PEF","1\\. Inclusion Criteria:\n\n1\\) Age ≥19 2) New York Heart Association (NYHA) II-III dyspnea 3) Diagnosis of HFpEF (Exams conducted within 6 months from screening) \\[must satisfy all (1), (2), and (3)\\]\n\n1. Left ventricular ejection fraction (LVEF) ≥50%\n2. NT-proBNP ≥220 pg\u002FmL or BNP ≥80 pg\u002FmL, if in sinus rhythm NT-proBNP ≥660 pg\u002FmL or BNP ≥240 pg\u002FmL, if in atrial fibrillation\n3. Satisfying either noninvasive or invasive criteria I. Noninvasive: Echocardiography with at least one of the following criteria\n\n   * LAVI ≥34 ml\u002Fm2\n   * Lateral E\u002Fe' ≥9\n   * LVMI ≥115 g\u002Fm2 if male or ≥95 g\u002Fm2 if female\n   * LV wall thickness ≥12mm II. Invasive: LVEDP ≥16mmHg or pulmonary capillary wedge pressure(PCWP) ≥15mmHg 4) Stable\u002Fchronic ambulatory patients without hospitalization within the last 30 days due to heart failure decompensation episode 5) Patients taking heart failure medication without change for at least 3 weeks before screening\n\n     2\\. Exclusion Criteria:\n     1. Unwillingness or inability to comply with the procedures described in this protocol\n     2. The ability to walk is, in the investigator's opinion, clearly limited by joint disease or other locomotor problems or lung diseases rather than by cardiorespiratory fitness\n     3. NYHA IV dyspnea\n     4. Type 1 diabetes mellitus\n     5. Estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73m2 (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula)\n     6. Anemia (Hb \\\u003C7g\u002FdL)\n     7. Severe hepatic impairment (Child-Pugh class C)\n     8. Acute myocardial infarction or unstable angina within 30 days before inclusion or planned coronary revascularization at the time of inclusion\n     9. Significant left-sided valvular heart disease (moderate to severe stenosis and severe regurgitation)\n     10. Heart failure due to any of the following: infiltrative cardiomyopathy (amyloidosis, sarcoidosis), active myocarditis, constrictive pericarditis, hypertrophic cardiomyopathy\n     11. Symptomatic hypotension (systolic blood pressure \\\u003C90mmHg)\n     12. Severe chronic obstructive pulmonary disease (postbronchodilator forced expiratory volume in 1 second (FEV1)\u002Fforced vital capacity(FVC) \\\u003C70% and FEV1 \\\u003C50%)\n     13. Treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) within 30 days before inclusion\n     14. History of diabetic ketoacidosis while in treatment with SGLT2i\n     15. Recurrent genitourinary tract infections\n     16. History of Hypersensitivity reaction to SGLT2i\n     17. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n     18. Female patients who are currently or planning to become pregnant\n     19. Female patients who are lactating\n     20. Patients participating in other clinical trials","19 Years",{"count":140,"type":21},154,[24],"The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF).",[144],"Heart Failure, Preserved Ejection Fraction",[146,147,148],"Heart failure with preserved ejection fraction","Sodium glucose cotransporter 2 inhibitors","Exercise performance","2024-04-05",{"date":151,"type":40},"2024-04-08",{"date":153,"type":21},"2024-05-01",{"date":155,"type":21},"2026-06-30",{"name":157,"class":47},"Samsung Medical Center",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":48},"100300921","characterization-of-heart-failure-with-preserved-ejection-fraction-100300921","NCT03197350","Characterization of Heart Failure With Preserved Ejection Fraction","Controls without an history of HF and previous cardiovascular disease will be recruited\n\nInclusion Criteria for HF patients:\n\nPatients need to have typical symptoms and signs of HF, New York Heart Association (NYHA) functional class II or higher, N-terminal pro-B type natriuretic peptide (NT-proBNP) \\>350pg\u002FmL, or an hospitalization for HF within the previous 12 months. Left ventricular ejection fraction (LVEF) is required to be lower than 40% in patients with HFrEF and 50% or higher in HFpEF, with evident signs of diastolic dysfunction ( LA \\> 34 ml\u002Fm²; E\u002Fe' \\> 14; TR \\>2.8 ms, septal e' velocity \\\u003C 7 cm\u002Fs or Lateral e' velocity \\\u003C10 cm\u002Fs)\n\nExclusion Criteria for HF patients:\n\nPatients with severe valvular disease, infiltrative or hypertrophic cardiomyopathy, acute coronary syndrome in the previous 30 days, chronic obstructive pulmonary disease GOLD 3 or 4, congenital heart disease, pericardial disease, terminal renal failure (eGFR \\\u003C 15mL\u002Fmin\u002F1,73m²) or subjects requiring dialysis, atrial fibrillation with a ventricular response \\> 140 bpm, severe anemia (hemoglobin \\\u003C 8 g\u002FdL), liver dysfunction, and evolving cancer will be excluded","99 Years",{"count":59,"type":21},[116],"The goals of this research will be to define some of the mechanisms underlying the progression and complications of heart failure (HF) with preserved left ventricular ejection fraction (HFPEF)\n\nAim 1: to evaluate the differences in cardiac structure, function and fibrosis markers through the spectrum of HF stages in order to deepen the understanding of the pathophysiology driving HF progression.\n\nAim 2: to define the mechanisms by which HF risk factors, such as hypertension, diabetes, obesity, and renal insufficiency, interact with age to increase HF risk, and to evaluate the role of precipitating factors such as myocardial ischemia, atrial fibrillation in HFPEF.\n\nAim 3: to determine prognostic factors in HFPEF patients, by following these patients over time. Accordingly the investigators will correlate baseline data (echocardiographic, MRI or biomarkers) with incident cardiovascular events and determine whether these measures provide incremental prognostic information beyond clinical characteristics.",[144,169,95,170],"Cardiac Fibrosis","Magnetic Resonance Imaging",[172,173,174],"heart failure with preserved ejection fraction","Imaging","Prognosis","2024-02-01",{"date":177,"type":40},"2024-02-05",{"date":179,"type":40},"2014-12-04",{"date":181,"type":21},"2028-12",{"name":183,"class":47},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain"]